Opinion|Videos|March 19, 2024

Diagnostic Practices in Prostate Cancer

Author(s)Matthew Smith, MD, PhD, Brian Helfand, MD, PhD

A comprehensive discussion on diagnostic practices in prostate cancer, highlighting imaging practices and the differences between castration-resistant prostate cancer and hormone-sensitive prostate cancer.

Episodes in this series

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 1 Screening for Prostate Cancer

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 2 Diagnostic Practices in Prostate Cancer

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 3 Treatment Decision-Making for Newly Diagnosed Metastatic Prostate Cancer

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 4 Overview of ARPIs in the Treatment of Prostate Cancer

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 5 Evolving Treatment Landscape in Prostate Cancer

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 6 Current Approaches to Treating Nonmetastatic CRPC

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 7 Metastatic Prostate Cancer Treatment Approach

Brian T. Helfand, MD, and Matthew Smith, MD, PhD, experts on prostate cancer

EP. 8 Future Directions in Prostate Cancer Treatment

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

ByAdam B. Weiner, MD,Tyler Seibert, MD, PhD

August 21st 2026

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

ByMary Dunn, MSN, NP-C, OCN, RN

August 20th 2026

SBRT improves multiple quality of life domains but not DFS vs MH-IMRT

ByHannah Clarke

August 18th 2026

Active surveillance use for low-risk prostate cancer reaches 93% in VA system

ByHannah Clarke

August 14th 2026

Focal therapy for prostate cancer frequently used outside guideline-supported groups

ByHannah Clarke

August 14th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy